Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Candel Therapeutics (CADL) Return on Sales (2020 - 2022)

Candel Therapeutics' Return on Sales history spans 3 years, with the latest figure at 2.54% for Q4 2022.

  • On a quarterly basis, Return on Sales rose 1038.0% to 2.54% in Q4 2022 year-over-year; TTM through Dec 2022 was 2.84%, a 24.0% decrease, with the full-year FY2022 number at 2.82%, down 24.0% from a year prior.
  • Return on Sales hit 2.54% in Q4 2022 for Candel Therapeutics, up from 2.92% in the prior quarter.
  • Over the last five years, Return on Sales for CADL hit a ceiling of 0.81% in Q2 2020 and a floor of 12.92% in Q4 2021.
  • Historically, Return on Sales has averaged 3.07% across 3 years, with a median of 2.54% in 2022.
  • Biggest five-year swings in Return on Sales: plummeted -1096bps in 2021 and later skyrocketed 1038bps in 2022.
  • Tracing CADL's Return on Sales over 3 years: stood at 1.96% in 2020, then tumbled by -559bps to 12.92% in 2021, then surged by 80bps to 2.54% in 2022.
  • Business Quant data shows Return on Sales for CADL at 2.54% in Q4 2022, 2.92% in Q3 2022, and 2.94% in Q2 2022.